Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Well, Amgen is a very intriguing potential investment right now. Its second quarter featured revenue up 9% year over year, ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...

Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug ...

The biotech company is Ventura County's largest private-sector employer, but most of its recent growth has happened outside ...

Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in ...

Biotech company invests in its roots in Thousand Oaks. On Tuesday, the business announced the building of a 'state-of-the-art ...

Amgen is putting down $600 million to build a new R&D site in California, a move the Big Pharma says will create hundreds of U.S. jobs.    | Amgen is putting down $600 million to build a new R&D site ...

Across the Phase 3 ROCKET program including ASCEND, the incidence of gastrointestinal ulceration events with rocatinlimab to date is less than 1 per 100 patient-years. The ASCEND study is ongoing and ...

One of the world’s largest biotechnology companies is planning a major expansion at its headquarters in Southern California, ...

Taoiseach says he will meet president if he travels for September event as US relationship ‘puts bread on the table’ ...